Literature DB >> 3097252

Inhibitory effects of the pineal hormone melatonin and underfeeding during the promotional phase of 7,12-dimethylbenzanthracene-(DMBA)-induced mammary tumorigenesis.

D E Blask, S M Hill, K M Orstead, J S Massa.   

Abstract

The effects of melatonin (Mel) and/or underfeeding (30% food restriction) on 7,12-dimethylbenzanthracene (DMBA)-induced mammary tumorigenesis were examined in female Sprague-Dawley rats fed a semipurified diet. During the promotional phase of tumorigenesis, the animals began receiving either daily afternoon Mel (250 micrograms) or saline vehicle injections s.c. for 15 weeks. As compared with fed animals, underfed rats had a lower tumor incidence, tumor number and size while the latency to onset and regression of tumors was increased. Melatonin in fed rats moderately suppressed tumor incidence and number. However, the combination of Mel treatment and underfeeding caused the most marked inhibition of tumorigenesis as compared with either treatment alone. These results indicate that Mel administration and/or underfeeding during the promotional phase inhibit DMBA-induced mammary tumorigenesis perhaps via neuroendocrine and/or peripheral endocrine mechanisms.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3097252     DOI: 10.1007/bf01243365

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  20 in total

Review 1.  The pineal and its hormones in the control of reproduction in mammals.

Authors:  R J Reiter
Journal:  Endocr Rev       Date:  1980       Impact factor: 19.871

Review 2.  Diet and cancer--an overview (second of two parts).

Authors:  W C Willett; B MacMahon
Journal:  N Engl J Med       Date:  1984-03-15       Impact factor: 91.245

3.  Influence of protein--calorie malnutrition on the circadian rhythm of pineal melatonin in the rat.

Authors:  D C Herbert; R J Reiter
Journal:  Proc Soc Exp Biol Med       Date:  1981-03

4.  Studies on the daily pattern of pineal melatonin in the Syrian hamster.

Authors:  L Tamarkin; S M Reppert; D C Klein; B Pratt; B D Goldman
Journal:  Endocrinology       Date:  1980-11       Impact factor: 4.736

5.  Pineal ablation in varying photoperiods and the incidence of 9,10-dimethyl-1,2-benzanthracene induced mammary cancer in rats.

Authors:  L S Kothari; P N Shah; M C Mhatre
Journal:  Cancer Lett       Date:  1984-02       Impact factor: 8.679

6.  Prolactin and murine mammary tumorigenesis: a review.

Authors:  C W Welsch; H Nagasawa
Journal:  Cancer Res       Date:  1977-04       Impact factor: 12.701

7.  Influence of underfeeding during the "critical period" or thereafter on carcinogen-induced mammary tumors in rats.

Authors:  P W Sylvester; C F Aylsworth; D A Van Vugt; J Meites
Journal:  Cancer Res       Date:  1982-12       Impact factor: 12.701

8.  Acute effects of a single afternoon melatonin injection on LH, prolactin, and pineal melatonin titers in the Syrian hamster.

Authors:  L J Petterborg; B A Richardson; M K Vaughan; R J Reiter
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

9.  Effects of melatonin on cancer: studies on MCF-7 human breast cancer cells in culture.

Authors:  D E Blask; S M Hill
Journal:  J Neural Transm Suppl       Date:  1986

10.  Relationship of hormones to inhibition of mammary tumor development by underfeeding during the "critical period" after carcinogen administration.

Authors:  P W Sylvester; C F Aylsworth; J Meites
Journal:  Cancer Res       Date:  1981-04       Impact factor: 12.701

View more
  9 in total

Review 1.  Sleep and circadian disruption and incident breast cancer risk: An evidence-based and theoretical review.

Authors:  Laura B Samuelsson; Dana H Bovbjerg; Kathryn A Roecklein; Martica H Hall
Journal:  Neurosci Biobehav Rev       Date:  2017-10-13       Impact factor: 8.989

Review 2.  Clinical aspects of the melatonin action: impact of development, aging, and puberty, involvement of melatonin in psychiatric disease and importance of neuroimmunoendocrine interactions.

Authors:  F Waldhauser; B Ehrhart; E Förster
Journal:  Experientia       Date:  1993-08-15

3.  Pineal melatonin inhibition of tumor promotion in the N-nitroso-N-methylurea model of mammary carcinogenesis: potential involvement of antiestrogenic mechanisms in vivo.

Authors:  D E Blask; D B Pelletier; S M Hill; A Lemus-Wilson; D S Grosso; S T Wilson; M E Wise
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

4.  Studies on the effects of the pineal hormone melatonin on an androgen-insensitive rat prostatic adenocarcinoma, the Dunning R 3327 HIF tumor.

Authors:  G R Buzzell
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

5.  Preventive and curative effect of melatonin on mammary carcinogenesis induced by dimethylbenz[a]anthracene in the female Sprague-Dawley rat.

Authors:  Véronique Lenoir; Marianne Beau Yon de Jonage-Canonico; Marie-Hélène Perrin; Antoine Martin; Robert Scholler; Bernard Kerdelhué
Journal:  Breast Cancer Res       Date:  2005-04-29       Impact factor: 6.466

Review 6.  Testing electromagnetic fields for potential carcinogenic activity: a critical review of animal models.

Authors:  J McCann; R Kavet; C N Rafferty
Journal:  Environ Health Perspect       Date:  1997-02       Impact factor: 9.031

7.  Expression of melatonin receptors in triple negative breast cancer (TNBC) in African American and Caucasian women: relation to survival.

Authors:  Gabriela Oprea-Ilies; Erhard Haus; Linda Sackett-Lundeen; Yuan Liu; Lauren McLendon; Robert Busch; Amy Adams; Cynthia Cohen
Journal:  Breast Cancer Res Treat       Date:  2012-12-19       Impact factor: 4.872

8.  A sequential treatment regimen with melatonin and all-trans retinoic acid induces apoptosis in MCF-7 tumour cells.

Authors:  K M Eck; L Yuan; L Duffy; P T Ram; S Ayettey; I Chen; C S Cohn; J C Reed; S M Hill
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

Review 9.  The glucocorticoid receptor signalling in breast cancer.

Authors:  Paraskevi Moutsatsou; Athanasios G Papavassiliou
Journal:  J Cell Mol Med       Date:  2007-12-05       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.